Dermata Therapeutics withdraws IND application for XYNGARI

As part of the Company’s strategic shift into the OTC marketplace, it has withdrawn its investigational new drug application for XYNGARI with FDA. The Company believes this strategic decision will provide greater flexibility to leverage the many novel features and benefits of its Spongilla technology in a variety of skin care products for the OTC marketplace. The Company plans to provide regular updates on the progress of this strategic shift and its upcoming OTC product launches, with the first product launch planned for mid-2026.